ARKG vs XBI

Key Takeaways

• ARKG is an actively managed thematic ETF focused on the genomics revolution, while XBI is a passively managed fund tracking a modified equal-weighted biotechnology index.
• ARK Genomic Revolution ETF (ARKG) maintains a concentrated portfolio of approximately 33-40 holdings with significant exposure to gene editing, sequencing, and AI-driven biotech companies.
• SPDR S&P Biotech ETF (XBI) offers broader diversification across roughly 160-165 holdings, providing more balanced exposure across the biotechnology sector.
• ARKG carries a higher expense ratio of 0.75% compared to XBI's 0.35%, reflecting its active management approach.
• Both ETFs target the healthcare and biotechnology space but differ in strategy, with ARKG emphasizing innovation themes and XBI delivering modified equal-weighted sector exposure.
• Structural differences in management style, concentration, and costs position the funds as complementary rather than direct competitors for investors seeking biotechnology exposure.

Introduction

ARK Genomic Revolution ETF (ARKG) and SPDR S&P Biotech ETF (XBI) both provide investors with targeted exposure to the biotechnology sector, yet they pursue distinct strategies. ARKG employs active management to capture companies advancing the genomics revolution, including gene therapy and molecular medicine. In contrast, XBI passively tracks a modified equal-weighted index of U.S. biotechnology firms. These ETFs appeal to investors seeking growth opportunities in healthcare innovation but differ in risk profiles, costs, and diversification. Comparing them helps clarify how thematic active strategies versus broad passive sector exposure perform within the same industry amid evolving regulatory and macroeconomic conditions.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing primarily in domestic and foreign equity securities of companies relevant to the genomics revolution. The fund typically holds 33-40 positions, with top holdings including 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), Tempus AI Inc. (TEM), CRISPR Therapeutics AG (CRSP), and Natera Inc. (NTRA). Allocations concentrate heavily in healthcare, particularly biotechnology and life sciences tools, with some technology exposure. The expense ratio stands at 0.75%. As an actively managed thematic vehicle, ARKG features flexible rebalancing based on ARK Investment Management's research rather than a fixed index. This structure allows emphasis on high-conviction genomics and precision medicine names but results in higher concentration and costs compared to passive alternatives.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) is a passively managed fund launched in 2006 that seeks to track the performance of the S&P Biotechnology Select Industry Index before fees and expenses. The index applies modified equal weighting to approximately 160-165 U.S. biotechnology companies spanning large-, mid-, and small-capitalization segments. Top holdings typically include Moderna Inc. (MRNA), Twist Bioscience Corp. (TWST), Natera Inc. (NTRA), AbbVie Inc. (ABBV), and Biogen Inc. (BIIB). The portfolio allocates nearly all assets to healthcare, with negligible exposure outside the sector. The expense ratio is 0.35%. XBI's structure promotes broader diversification and lower costs through rules-based, modified equal-weighted methodology with periodic rebalancing to maintain index alignment. This approach reduces single-stock risk relative to more concentrated active strategies.

Industry and Thematic Backdrop

The biotechnology sector continues to benefit from advances in gene editing, personalized medicine, and AI integration in drug discovery. Regulatory pathways for novel therapies, ongoing clinical trial progress, and potential capital inflows into innovative healthcare remain key catalysts. Macroeconomic factors such as interest rate expectations influence sector valuations, as many biotechnology firms rely on future cash flows. Broader healthcare spending trends and intellectual property protections also shape the environment. Risks include clinical trial failures, reimbursement pressures, and heightened regulatory scrutiny. Both ARKG and XBI operate within this dynamic landscape, where innovation cycles and policy developments can drive relative performance across thematic and broad biotechnology exposures.

Performance and Positioning Comparison

In recent market cycles, ARKG's concentrated thematic approach has produced higher volatility tied to the success of specific genomics and gene-editing holdings. XBI's modified equal-weighted construction has delivered more stable sector representation, with performance influenced by broader biotechnology earnings trends and rotation within healthcare. During periods of strong innovation momentum, ARKG may exhibit greater upside from high-conviction positions, while XBI tends to capture diversified participation across clinical-stage and commercial biotechs. Interest rate sensitivity and capital allocation shifts within the sector have historically affected both funds, though XBI's lower expense ratio and wider diversification support more consistent positioning across market regimes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

Tickeron AI Verdict

Based on structural strength, cost efficiency, and diversification profile, Tickeron’s AI would currently assign a higher probability of favor to SPDR S&P Biotech ETF (XBI). Its lower expense ratio, broader holdings, and modified equal-weighted methodology provide more consistent sector exposure with reduced concentration risk in the current biotechnology environment. ARK Genomic Revolution ETF (ARKG) offers compelling thematic depth for investors prioritizing genomics innovation but carries higher costs and volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations